Boule Diagnostics AB (BOUL) - Total Liabilities
Based on the latest financial reports, Boule Diagnostics AB (BOUL) has total liabilities worth Skr303.90 Million SEK (≈ $32.70 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Boule Diagnostics AB - Total Liabilities Trend (2005–2024)
This chart illustrates how Boule Diagnostics AB's total liabilities have evolved over time, based on quarterly financial data. See BOUL working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Boule Diagnostics AB Competitors by Total Liabilities
The table below lists competitors of Boule Diagnostics AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Imexhs Ltd
AU:IME
|
Australia | AU$8.36 Million |
|
Melbana Energy Ltd
AU:MAY
|
Australia | AU$24.24 Million |
|
Young Heung I&
KO:012160
|
Korea | ₩235.50 Billion |
|
Mynd.ai, Inc.
NYSE MKT:MYND
|
USA | $203.97 Million |
|
Future Retail Limited
NSE:FRETAIL
|
India | Rs12.21 Billion |
|
SAIHEAT Limited
NASDAQ:SAIH
|
USA | $4.17 Million |
|
Prospera Energy Inc
V:PEI
|
Canada | CA$69.63 Million |
|
Mentiga Corporation Bhd
KLSE:5223
|
Malaysia | RM120.95 Million |
Liability Composition Analysis (2005–2024)
This chart breaks down Boule Diagnostics AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Boule Diagnostics AB.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.10 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Boule Diagnostics AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Boule Diagnostics AB (2005–2024)
The table below shows the annual total liabilities of Boule Diagnostics AB from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr320.60 Million ≈ $34.50 Million |
+14.50% |
| 2023-12-31 | Skr280.01 Million ≈ $30.13 Million |
-5.87% |
| 2022-12-31 | Skr297.46 Million ≈ $32.01 Million |
+7.66% |
| 2021-12-31 | Skr276.30 Million ≈ $29.73 Million |
+31.32% |
| 2020-12-31 | Skr210.41 Million ≈ $22.64 Million |
-17.16% |
| 2019-12-31 | Skr254.00 Million ≈ $27.33 Million |
+27.00% |
| 2018-12-31 | Skr199.99 Million ≈ $21.52 Million |
+29.26% |
| 2017-12-31 | Skr154.72 Million ≈ $16.65 Million |
+14.98% |
| 2016-12-31 | Skr134.57 Million ≈ $14.48 Million |
+5.98% |
| 2015-12-31 | Skr126.97 Million ≈ $13.66 Million |
+15.47% |
| 2014-12-31 | Skr109.96 Million ≈ $11.83 Million |
+17.95% |
| 2013-12-31 | Skr93.23 Million ≈ $10.03 Million |
+23.42% |
| 2012-12-31 | Skr75.54 Million ≈ $8.13 Million |
-4.37% |
| 2011-12-31 | Skr78.99 Million ≈ $8.50 Million |
+4.55% |
| 2010-12-31 | Skr75.55 Million ≈ $8.13 Million |
+55.85% |
| 2009-12-31 | Skr48.47 Million ≈ $5.22 Million |
-8.79% |
| 2008-12-31 | Skr53.14 Million ≈ $5.72 Million |
+3.61% |
| 2007-12-31 | Skr51.29 Million ≈ $5.52 Million |
+10.69% |
| 2006-12-31 | Skr46.34 Million ≈ $4.99 Million |
+9.63% |
| 2005-12-31 | Skr42.27 Million ≈ $4.55 Million |
-- |
About Boule Diagnostics AB
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clini… Read more